I heard that one in seven thousand people using GLP drugs developed vision problems and even blindness from a condition called NAION. Earlier figures put it at one in ten thousand. How realistic are these serious side effects with GLP medications? One report noted that over five years of tracking everyone with type 2 diabetes in Denmark, weekly semaglutide more than doubled the chance of NAION on its own. Because NAION cannot be reversed, the risk should be recognized and future research should look for groups most likely to be affected.
Question about side effects
Summary
how common and realistic is the risk of NAION blindness with GLP-1 drugs like semaglutide
Users discuss reports that semaglutide more than doubles NAION risk in type 2 diabetes patients, with incidence rising from roughly 1 in 10,000 to 1 in 7,000. Several note the absolute risk remains low even after the relative increase, and no widespread reports of sudden blindness have surfaced despite high usage numbers. Older alerts from health authorities about retinal vascular issues were mentioned but later removed. Participants agree monitoring is prudent for long-term diabetic patients but differ on whether the drug itself is the direct cause versus other factors like medication changes.
What this discussion establishes- NAION incidence roughly doubles with semaglutide but stays under 11 per 100,000 person-years
- absolute risk described as very low even after the increase
- problem linked mainly to long-standing type 2 diabetes rather than GLP-1 use alone
- older French health authority alert on retinal vascular risks was issued then withdrawn
- regular ophthalmologist visits recommended for anyone on these medications
whether semaglutide directly causes NAION or if the association stems from stopping protective drugs like metformin or from rapid glucose drops
Still openexact mechanism and whether newer data still support the doubled risk after longer follow-up
Nothing here is advice.
15 replies · 8 people
I figure their sight got wrecked from peering at the small print they put out.
↳ replying to @SharpAnchor64 (opening post)
If that eleven percent figure applies just to this country it suggests more than five thousand cases of lost vision. You'd think there'd be greater discussion around such numbers. Plus I'm curious about the origin of those numbers.
↳ replying to @PatientBeacon15
The amount they slimmed down left their lids drooping low enough to block their view.
↳ replying to @BrightSparrow36
This detail belongs in the official instructions included with the medication. Unfortunately it leads to loss of vision at a rate higher than one would have thought.
↳ replying to @SharpAnchor64
Where did you see that figure about one out of seven thousand reta users losing their sight? Got a link to the research?
Roughly a year and a half earlier a French health body sent word to physicians especially eye specialists to watch for possible severe blood vessel troubles in the retina among people using certain GLP-1 medicines. I brought the notice up at my next eye exam and the doctor had not heard of it. The original posting vanished before the appointment yet a cached search version let me display the details anyway. Nothing further on the subject has appeared since.
Reading through this the rate comes out lower for that drug. Starting details showed folks around age 65 with a blood sugar marker at 50 and just over half male. Across almost two million years of following people 218 cases appeared. That gives roughly ten per hundred thousand against the usual eleven. NAION brings sudden painless sight loss in one eye plus matching field cuts. Its cause stays unclear yet probably ties to weak blood supply at the optic nerve. It occurs at eleven per hundred thousand yearly and counts as the leading type of eye nerve damage.
From what I've come across, NIAON does occur even if the details stay unclear in my memory of the material. It struck me that an abrupt fall in glucose among people with diabetes might tie into it somehow.
↳ replying to @GreyAlder39
A review combining data from multiple studies points to a clear connection between semaglutide and NAION among people managing type 2 diabetes, unlike those using other treatments in the same class. The connection stays noticeable even when use stretches beyond five years. It draws from both a pooled analysis and a systematic examination dated May 27 2026.
↳ replying to @SharpAnchor64
Thanks for that. I looked up papers that reference the original research and found updated information from July 2025. This focuses on individuals who have had type 2 diabetes for many years. The writers point out that missing details on this for every participant restricts their analysis. They left out those using metformin to prevent skewing the numbers of vascular complications, given how it shields against such issues.
Looks like you've gone and revised that very first message of yours.
↳ replying to @SharpAnchor64
That piece appeared back in May yet it skips over the source I mentioned before. Nothing so far shows this issue stems purely from those GLP-1 drugs instead of stopping or lowering my other prescriptions. Diabetics already see an eye specialist once a year. I simply raised the topic at my own checkup and that took care of the follow-up.
↳ replying to @NorthWillow72
From what I've gathered the odds start near half a case per hundred thousand no matter the age and rise to somewhere from two up to ten among those older than fifty. Reports from about a year back suggested these drugs roughly doubled the odds. That amounts to a sizable jump when viewed proportionally yet the raw numbers stay tiny. A brief check of the research indicates the odds could edge up slightly for folks with diabetes though the raw numbers stay tiny.
Add your experience
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.